Good morning, and welcome to IM Cannabis's third quarter 2024 earnings conference call. Today's conference call is being recorded. At this time, I would like to turn the conference call over to Anna Taranko, Director of Investor and Public Relations. Anna? Good morning, and thank you, Operator. Joining me for today's call are IM Cannabis Chief Executive Officer Oren Shuster and Chief Financial Officer Uri Birenberg. The earnings press release that accompanies this call is available on the Investor Relations section of our website at investors.imcannabis.com. Today's call will include estimates and other forward-looking information and statements, including statements concerning future results of operations, economic conditions, and anticipated courses of action, and are based on assumptions, expectations, estimates, and projections as the date hereof. This information may involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences are described in detail in the company's most recent filings available on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov. Furthermore, certain non-IFRS measures will be referred to during this call, and the term non-IFRS Adjusted EBITDA loss will hereafter be referred to as Adjusted EBITDA loss. Any estimates or forward-looking information or statements provided are accurate only as of the date of this call, and the company undertakes no obligation to publicly update any forward-looking information or statements, or supply new information regarding the circumstances after the date of this call. Please also note that all references on this call reflect currency in Canadian dollars. With that, it is my pleasure to turn the call over to Oren Shuster, CEO of IM Cannabis. Oren, please go ahead. Thank you, Anna. Good morning, everyone, and thank you for joining us today. In Q3, we had a clear focus: to build a solid foundation to deliver accelerated growth in Germany in 2025. That said, as a medical cannabis company active in Israel and in Germany, I will start with a quick overview of the development of the German market and our performance there before explaining the progress we made to position the company for 2025. Since the April 1st partial legalization, the German cannabis market has been experiencing unprecedented growth at the speed that I don't think many anticipated. The growth has been driven by the increasing number of patients opting for cannabis-based treatments and the relatively inexpensive, easy-to-prescription process. Advances in medical research, better accessibility through pharmacies, and the growing number of healthcare professionals willing to prescribe cannabis for a range of conditions, from chronic pain to anxiety and sleep disorders, are also key factors. The easing of regulations and increased public awareness have contributed significantly to the expansion of the market as well. As I did in the last quarter, I would like to put this growth into perspective by taking you through the details of our sales in Germany in 2024. They clearly show that the strategic shift we made to concentrate our resources on the German market was the right one. Our sales increased by over 200% in Q2 versus Q1 to reach CAD 3.5 million. In Q3, we again increased our sales by 66% versus Q2 to reach CAD 5.8 million in Q3. Since Q2, we have been driving the market growth and are positioned among the top cannabis companies in Germany. While I'm very proud to be presenting these numbers, our focus in the last few months has actually been behind the scenes on building a solid foundation for 2025. We spent the quarter leaning further into a clear target: full integration of the German and Israeli teams. The goal was to build a strong, consistent supply chain and a laser-focused approach on how to improve the efficiency and accuracy of how we use our resources. I believe that this foundation will be the basis to drive accelerated growth in Germany in 2025. Behind every success, there is a strong, unified team. In Q2, the Israeli and German colleagues started working very closely to build a new supply channel from Israel to Germany. Cannabis supply chains are notoriously difficult to build with all the local, regional, and international regulations that need to be followed. They managed this in record time. The first three Israeli growth strains launched in Q3. The teamwork behind these first three strains is gathering steam and has led to new projects and opportunities. We are in the process of onboarding several new suppliers and expect to see the results during 2025. Just as important as a stable supply chain to deliver growth is efficient resource management to sustain the growth. Our Q3 2024 revenues increased from CAD 12.4 million in Q3 2023 to CAD 13.9 million this quarter, while our operating expenses decreased from CAD 4.9 million in Q3 2023 to CAD 4.1 million in Q3 2024. As a result, our operating expenses ratio was 30% in Q3 2024 in comparison with 40% in Q3 2023, a remarkable 25% increase in efficiency. This decrease has been driven by several factors, but the integration between the two teams has been fundamental. By sharing the same resources, we have been able to significantly lower costs. Our active cost management has stretched through all aspects of the business, from purchasing and logistics to sales and marketing, making our execution much more efficient. Our goal is to keep this foundation to drive sustainable growth in 2025. While our journey to lean and agile company over the last year has not always been easy, I'm very proud of how efficient we have become, how well we are using our resources to deliver growth. The progress we have already made on both the supply chain and our sales efficiency gives us a very strong foundation to deliver accelerated growth in Germany in 2025. Taking a look at our Israeli business, as in Q2, we continue to shift resources to support the German business and continue to work toward maximizing our profitability in Israel. For our Israeli business, this translates into a clear focus on the premium and ultra-premium markets. Over the past few months, our market has been influenced by several factors. The ongoing war has continued to impact our supply chain, causing delays in shipments. We have also seen a reduction in the number of medical cannabis patients, with a decline of 10% from July to October. While the war initially delayed the medical cannabis license renewal process, it does not explain this sustained decrease. In the absence of sufficient data, we assume that the changes brought about by the July 2024 reform are causing complications in the prescription process. On the operational level, in our Israeli business, we relaunched Lot 420, a premium Canadian brand with a total of three strains. All three strains were very well received by the market, selling through quickly. The same occurred with Super Sativa, the leading strain in our IMC Craft brand. These results clearly show how we can capitalize on our understanding of both the premium market drivers as well as the patients' needs to deliver sales. As in the previous quarters, we are continuing to clean our slow-moving non-premium stock, clearing out old inventory for about CAD 0.6 million, which again impacted our cost of sales, gross margin, and gross profit. To sum up Q3 2024, while the growth IMC delivered in Germany is clearly a highlight, most importantly, we focused on building a solid foundation, fully integrating the two teams to strengthen our supply chain and drive efficiencies that will be the basis to deliver accelerated growth in 2025 in Germany. I will now hand the call over to Uri, who will review the third quarter 2024 financial results. Uri? Thank you, Oren. Our Q3 results were mainly impacted by the following points. Our revenue in Q3 increased by 12.2% versus Q3 2023. This growth was driven mainly by an increase of 278% in the German revenue. Our selling price per gram of the dried flower increased 42% in this time period to CAD 6.2 per gram. In addition, our operating expenses decreased by 16% versus Q3 2023. We continued closely monitoring our inventory and accrued for about CAD 0.6 million for slow-moving stock. The mid-April Oranim Pharm agreement revocation resulted in reduced revenue and expenses versus previous periods. I will now take you through the overview of the Q3 2024 financial results for the company's operations. Revenue for the nine months ended September 30, 2024, and 2023 were CAD 40.7 million and CAD 38.1 million, respectively, representing an increase of CAD 2.6 million, or 7%. The increase is mainly attributed to the accelerated growth in Germany, with an increase in revenue of CAD 6.3 million and decreased revenue in Israel of CAD 3.7 million net. The decrease in Israel is attributed to the Oranim Pharm deal cancellation, which resulted in a decrease in revenue of approximately CAD 5.1 million compared to the nine months ended September 2023. Excluding the Oranim Pharm revenue in Q3 2023, we have an increase of revenue in Israel as well of approximately CAD 1.4 million, or 6%. Revenue for the three months ended September 30, 2024, and 2023 were CAD 13.9 million and CAD 12.4 million, respectively, representing an increase of CAD 1.5 million, or 12%. The increase is mainly attributed to the accelerated growth in Germany, with an increase in revenue of CAD 4.3 million and decreased revenue in Israel of CAD 2.8 million net. The decrease in Israel is attributed to the Oranim Pharm deal cancellation, which resulted in a decrease in revenue of CAD 3.2 million compared to the three months ended September 2023. Excluding the Oranim Pharm revenue in Q3 2023, we have an increase in revenue as well in Israel of approximately CAD 0.4 million, or 5%. Total dried flower sold for the nine months ended September 30, 2024, was 6,408 kilograms at an average selling price of CAD 6.01 per gram, compared to 6,528 kilograms for the same period in 2023 at an average selling price of CAD 5.34 per gram. For the three months ended September 30, 2024, total dried flower sold was 2,202 kilograms at an average selling price of CAD 6.2 per gram, compared to 2,558 kilograms for the same period in 2023 at an average selling price of CAD 4.35 per gram, mainly attributed to the inventory life cycle, product diversity, discounts given, and increased competition in the region. For the nine and three months ended September 30, 2024, Germany's share of total revenue has significantly increased compared to the corresponding period in 2023. This increase has had a considerable impact, reflecting in a higher average price due to the favorable market conditions and growing demands. Together, these factors have contributed to an overall positive effect on our revenue performances. The cost of revenue for the nine months ended September 30, 2024, and 2023 were CAD 34.9 million and CAD 28.4 million, respectively, representing an increase of CAD 6.5 million, or 23%. This is mainly due to the increase of material cost of approximately CAD 7.1 million, of which clearing all raw material of approximately CAD 0.94 million accrued for slow inventory of approximately CAD 2.2 million and increased inventory sales resulted in an increase of approximately CAD 4 million, which is offset by a reduced in other cost net of approximately CAD 0.6 million. The cost of revenue for the three months ended September 30, 2024, and 2023 were CAD 10.7 million and CAD 9.6 million, respectively, representing an increase of CAD 1.1 million, or 11%. This is mainly due to the increased cost of approximately CAD 1.2 million, including an accrual of CAD 0.6 million for slow inventory. This is offset by a decrease in other cost net of approximately CAD 0.1 million. Gross profit for the nine months ended September 30, 2024, and 2023 were CAD 5.8 million and CAD 9 million, respectively, representing a decrease of CAD 3.2 million, or 36%. Gross profit for the three months ended September 30, 2024, and 2023 were CAD 3.1 million and CAD 2.6 million, respectively, representing an increase of CAD 0.5 million, or 19%. Gross profit, including losses from realized fair value adjustment on inventory sold, was CAD 0.05 million and CAD 0.7 million for the nine months ended September 30, 2024, and 2023, respectively. Gross margin after fair value adjustment in the nine months ended September 30, 2024, and 2023, respectively, was 14% versus 25% and 23% versus 21% for the three months ended September 30, 2024, and 2023. G&A expenses for the nine months ended September 30, 2024, and 2023 were CAD 6.8 million and CAD 7.7 million, respectively, representing a decrease of CAD 0.9 million, or 11%. General and administrative expenses for the three months ended September 30, 2024, and 2023 were CAD 2.4 million and CAD 2.1 million, respectively, representing an increase of CAD 0.3 million, or 10%. The G&A expenses are comprised mainly from salaries to employees in the amount of CAD 1.6 million and CAD 0.5 million for the nine and three months ended September 30, 2024, professional fees in the amount of CAD 2.3 million and CAD 0.9 million for the nine and three months ended September 30, 2024, depreciation and amortization in the amount of CAD 0.4 million and CAD 0.14 million for the nine and three months ended September 30, 2024, insurance cost of an amount of CAD 1 million and CAD 0.34 million for the nine and three months ended September 30, 2024, and other expenses in a total amount of CAD 1.5 million and CAD 0.5 million for the nine and three months ended September 30, 2024. Selling and marketing expenses for the nine months ended September 30, 2024, and 2023 were CAD 5.3 million and CAD 8 million, respectively, representing a decrease of CAD 2.7 million, or 34%. Selling and marketing expenses for the three months ended September 30, 2024, and 2023 were CAD 1.5 million and CAD 2.6 million, respectively, representing a decrease of CAD 1.1 million, or 41%. The decrease in selling and marketing expenses for the nine and three months ended September 30, 2024, is mainly attributed to the Oranim Pharm revoked agreement of approximately CAD 1.3 million and CAD 0.7 million, respectively, in addition to a decrease of CAD 1.4 million and CAD 0.3 million, respectively, in selling and marketing expenses. Total operating expenses for the nine months ended September 2024 and 2023 were CAD 15.2 million and CAD 16.6 million. In Q3 2024, the total operating expenses were CAD 4.1 million compared to CAD 4.9 million in Q3 2023, a decrease of CAD 0.8 million, or 16%, mainly due to a decrease in salaries of approximately CAD 0.3 million, depreciation expenses of CAD 0.2 million, and insurance of CAD 0.1 million. Operating expenses ratio for the nine months ended September 30, 2024, was 31%, excluding the one-time expense outcome of Oranim Pharm deal cancellation, versus 44% for the nine months ended September 30, 2023, representing an increased efficiency of about 30%. Operating expenses ratio for the three months ended September 30, 2024, was 30% versus 40% for the three months ended September 30, 2023, representing an increased efficiency of about 25%. The efficiency ratio improvement is resulting from the increased operational cost and increased revenue. Non-IFRS adjusted EBITDA loss for the nine months ended September 2024 and 2023 was CAD 4.7 million, compared with CAD 3.7 million, representing an increase of 25%. Non-IFRS adjusted EBITDA loss in Q3 2024 was CAD 0.2 million, compared to an EBITDA loss of CAD 1.3 million in Q3 2023, representing an increase of 82%. Net loss in the nine months ended September 2024 was 10.6 million, compared to 6.7 million in the nine months ended September 2023. Net loss in Q3 2024 was 1.1 million, compared to 2.1 million in Q3 2023. Diluted loss per share for the nine months ended September 2024 was $4.29, compared to a loss of $2.95 per share in the same period for year 2023. Diluted loss per share for Q3 2024 was $0.41, compared to a loss of $0.96 per share in Q3 2023. As of the balance sheet, cash and cash equivalents as of September 30, 2024, were 2 million, compared to 1.8 million on December 31, 2023. Total assets as of September 30, 2024, were 44.6 million, compared to 48.8 million on December 31, 2023, a decrease of 4.2 million, or 8.6%. The decrease is mainly attributed to the Oranim Pharm agreement cancellation of CAD 9.5 million, of which mainly attributed to goodwill of CAD 3.5 million, intangible asset CAD 1.4 million, inventory CAD 0.8 million, trade receivables CAD 1.3 million, property plant and equipment CAD 0.8 million, and reduction of cash and cash equivalent of approximately CAD 0.3 million. In addition to Oranim Pharm revocation agreement effect, there is a total asset increase of CAD 5.3 million, mainly due to an increase of CAD 8.1 million in trade receivables and an increase of cash and cash equivalent of CAD 0.5 million, offset by CAD 4.8 million reduction in inventory and reduction of CAD 0.9 million in intangible assets. Total liabilities as of September 30, 2024, were CAD 40.4 million, compared to CAD 35.1 million on December 31, 2023, an increase of CAD 5.3 million, or 15%. The decrease was mainly due to the Oranim Pharm agreement cancellation of CAD 6.8 million, of which mainly attributed to put option liability CAD 2 million, purchase consideration payable CAD 2.2 million, trade payables CAD 1.6 million, lease liabilities CAD 0.4 million, and a decrease of CAD 0.3 million in deferred tax liability. In addition to the Oranim Pharm revocation agreement effect, there is a total liability increase of CAD 12.1 million, mainly due to an increase of CAD 8.9 million in trade payables and an increase of CAD 1.6 million in other accounts payable. The company is planning to finance its operation from existing and future working capital resources, as well as from available credit facilities, and will continue to evaluate additional sources of capital and financing as needed. I would now like to turn the call back to you, Oren, for closing remarks. Oren? Thank you. While the growth we delivered in Germany this quarter is a highlight, we spent the quarter focused on building a solid foundation for 2025. We leaned further into the full integration of the German and Israeli teams. Our goal was to build a strong, consistent supply chain, along with a laser focus on how to improve the efficiency and accuracy of how we use our resources. I believe that the foundation we built this quarter will be the basis to drive further accelerated growth in Germany in 2025. I will now hand the call over to the operator to begin our question and answer session. Operator? Thank you. To ask a question, please raise your hand using your mobile or desktop application or press star 9 on your telephone keypad and wait for your name to be called. I repeat, to ask a question, please raise your hand using your mobile or desktop application or press star 9 on your telephone keypad and wait for your name to be called. Okay. Now, no questions. So thank you, Operator, and thank you all for joining our call today.